About NewLink Genetics (NASDAQ:NLNK)
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555
Debt
Debt-to-Equity RatioN/A
Current Ratio7.96%
Quick Ratio7.96%
Price-To-Earnings
Trailing P/E Ratio-1.95
Forward P/E Ratio-1.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.71 million
Price / Sales5.81
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.10
Profitability
EPS (Most Recent Fiscal Year)($2.30)
Net Income$-71,950,000.00
Net Margins-250.60%
Return on Equity-60.60%
Return on Assets-47.48%
Miscellaneous
Employees76
Outstanding Shares37,160,000
NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions
What is NewLink Genetics' stock symbol?
NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."
How were NewLink Genetics' earnings last quarter?
NewLink Genetics Corp (NASDAQ:NLNK) posted its quarterly earnings results on Thursday, March, 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.32. The biotechnology company had revenue of $10.10 million for the quarter, compared to analyst estimates of $2.72 million. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. View NewLink Genetics' Earnings History.
When is NewLink Genetics' next earnings date?
What price target have analysts set for NLNK?
6 brokerages have issued 12 month price targets for NewLink Genetics' shares. Their predictions range from $5.00 to $25.00. On average, they anticipate NewLink Genetics' share price to reach $13.50 in the next year. View Analyst Ratings for NewLink Genetics.
What are Wall Street analysts saying about NewLink Genetics stock?
Here are some recent quotes from research analysts about NewLink Genetics stock:
- 1. Cantor Fitzgerald analysts commented, "Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point." (4/16/2018)
- 2. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (1/4/2018)
Who are some of NewLink Genetics' key competitors?
Some companies that are related to NewLink Genetics include Merus (MRUS), Kadmon (KDMN), Durect (DRRX), Seres Therapeutics (MCRB), BioSpecifics Technologies (BSTC), AVEO Pharmaceuticals (AVEO), Celyad (CYAD), Zymeworks (ZYME), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Avadel Pharmaceuticals (AVDL), Savara (SVRA), Selecta Biosciences (SELB), Minerva Neurosciences (NERV), Syndax Pharmaceuticals (SNDX), Kindred Biosciences (KIN), Catalyst Pharmaceuticals (CPRX) and ArQule (ARQL).
Who are NewLink Genetics' key executives?
NewLink Genetics' management team includes the folowing people:
- Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer (Age 56)
- Nicholas N. Vahanian M.D., President (Age 47)
- John Bell Henneman III, Chief Financial Officer, Secretary (Age 55)
- Eugene P. Kennedy M.D., Chief Medical Officer (Age 49)
- Brian Wiley, Chief Commercial Officer (Age 48)
- Thomas A. Raffin M.D., Lead Independent Director (Age 68)
- Paolo Pucci, Director (Age 56)
- Paul R. Edick, Independent Director (Age 62)
- Ernest J. Talarico III, Independent Director (Age 44)
- Lota S. Zoth CPA, Independent Director (Age 57)
Has NewLink Genetics been receiving favorable news coverage?
News headlines about NLNK stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NewLink Genetics earned a daily sentiment score of 0.07 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of NewLink Genetics?
Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NewLink Genetics' stock price today?
One share of NLNK stock can currently be purchased for approximately $4.49.
How big of a company is NewLink Genetics?
NewLink Genetics has a market capitalization of $167.57 million and generates $28.71 million in revenue each year. The biotechnology company earns $-71,950,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. NewLink Genetics employs 76 workers across the globe.
How can I contact NewLink Genetics?
NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE SUITE 5100, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]
MarketBeat Community Rating for NewLink Genetics (NLNK)
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
NewLink Genetics (NASDAQ:NLNK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for NewLink Genetics in the last 12 months. Their average twelve-month price target is $13.50, suggesting that the stock has a possible upside of 200.67%. The high price target for NLNK is $25.00 and the low price target for NLNK is $5.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Buy | Buy | Buy |
| Consensus Rating Score: | 2.17 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.50 | $23.6667 | $25.6667 | $25.8333 |
| Price Target Upside: | 200.67% upside | 211.81% upside | 203.57% upside | 129.63% upside |
NewLink Genetics (NASDAQ:NLNK) Consensus Price Target History
NewLink Genetics (NASDAQ:NLNK) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
NewLink Genetics (NASDAQ:NLNK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NewLink Genetics (NASDAQ NLNK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.30%
Institutional Ownership Percentage: 65.05%
NewLink Genetics (NASDAQ NLNK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2017 | Carl W. Langren | Insider | Sell | 2,229 | $9.05 | $20,172.45 | |  |
| 10/6/2017 | Stine Seed Farm, Inc. | Major Shareholder | Buy | 780,487 | $10.25 | $7,999,991.75 | 7,857,732 | |
| 3/15/2016 | Charles J Jr. Link | CEO | Sell | 25,000 | $17.86 | $446,500.00 | 297,756 | |
| 1/6/2016 | Charles J. Jr. Link | CEO | Sell | 25,000 | $32.53 | $813,250.00 | 342,756 | |
| 1/5/2016 | Brian Wiley | VP | Sell | 1,295 | $34.99 | $45,312.05 | 19,942 | |
| 1/5/2016 | Carl W. Langren | insider | Sell | 1,095 | $34.97 | $38,292.15 | 13,465 | |
| 1/5/2016 | Charles J. Jr. Link | CEO | Sell | 5,001 | $35.06 | $175,335.06 | 342,756 | |
| 1/5/2016 | John B. Henneman III | CFO | Sell | 175 | $35.74 | $6,254.50 | 62,316 | |
| 10/7/2015 | Charles J. Jr. Link | CEO | Sell | 10,000 | $35.16 | $351,600.00 | 371,118 | |
| 10/5/2015 | Charles J. Jr. Link | CEO | Sell | 15,000 | $37.36 | $560,400.00 | 371,118 | |
| 7/13/2015 | Joseph Saluri | Director | Sell | 5,000 | $50.42 | $252,100.00 | | |
| 7/6/2015 | Charles J Jr. Link | CEO | Sell | 20,000 | $44.65 | $893,000.00 | | |
(Data available from 1/1/2013 forward)
NewLink Genetics (NASDAQ NLNK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
finance.yahoo.com - April 20 at 5:21 PM |
 | NewLink Genetics (NLNK) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 8:34 PM |
| NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
finance.yahoo.com - April 17 at 5:54 PM |
| Zacks: Analysts Expect NewLink Genetics Corp (NLNK) Will Post Quarterly Sales of $5.78 Million
www.americanbankingnews.com - April 17 at 1:50 AM |
 | NewLink down 8% after bailing on indoximod in melanoma study
seekingalpha.com - April 16 at 5:24 PM |
 | Early data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibition
globenewswire.com - April 16 at 8:16 AM |
| NewLink Genetics' (NLNK) Hold Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 16 at 7:11 AM |
| Analysts Anticipate NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 15 at 11:10 PM |
 | NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for
www.nasdaq.com - April 15 at 6:35 PM |
| Jefferies Group Reiterates "Hold" Rating for NewLink Genetics (NLNK)
www.americanbankingnews.com - April 12 at 11:17 AM |
| NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
finance.yahoo.com - April 10 at 8:27 AM |
| NewLink Shares Plunge After Incyte & Merck's Study Fails
finance.yahoo.com - April 10 at 8:27 AM |
| New Research Coverage Highlights Golden Star Resources, Ryanair, Sasol, Access National, NewLink Genetics, and Canadian Pacific Railway — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - April 10 at 8:27 AM |
 | NewLink Shares Plunge After Incyte & Merck's Study Fails
www.zacks.com - April 9 at 5:21 PM |
 | UPDATE: Baird Downgrades NewLink Genetics (NLNK) to Neutral Citing IDO Concerns
www.streetinsider.com - April 9 at 5:21 PM |
| UPDATE: Cantor Fitzgerald Downgrades NewLink Genetics (NLNK) to Neutral
www.streetinsider.com - April 9 at 5:21 PM |
| NewLink Genetics (NLNK) Rating Lowered to Hold at Robert W. Baird
www.americanbankingnews.com - April 9 at 7:55 AM |
| NewLink Genetics (NLNK) Lowered to "Hold" at Cantor Fitzgerald
www.americanbankingnews.com - April 9 at 7:55 AM |
| SunTrust Robinson Humphrey Downgrades NewLink Genetics (NLNK) to Hold
www.streetinsider.com - April 7 at 8:25 AM |
| NewLink Genetics (NLNK) Downgraded by Jefferies Group to "Hold"
www.americanbankingnews.com - April 6 at 9:16 PM |
 | NewLink Genetics shares plummet 39% after Merck, Incyte trial failure
www.marketwatch.com - April 6 at 5:41 PM |
| Incyte's late-stage epacadostat flop pressures NewLink Genetics, down 32% premarket
seekingalpha.com - April 6 at 5:41 PM |
| NewLink Genetics Announces Review of Clinical Programs
www.nasdaq.com - April 6 at 5:41 PM |
| Why Incyte and NewLink Genetics Crashed Today
finance.yahoo.com - April 6 at 5:41 PM |
| NewLink Genetics (NLNK) Lowered to "Neutral" at Bank of America
www.americanbankingnews.com - April 6 at 4:14 PM |
| SunTrust Banks Downgrades NewLink Genetics (NLNK) to Hold
www.americanbankingnews.com - April 6 at 1:23 PM |
| Cantor Fitzgerald Analysts Give NewLink Genetics (NLNK) a $26.00 Price Target
www.americanbankingnews.com - April 6 at 12:11 PM |
 | Technical Perspectives on Biotech Stocks -- Neptune Technologies & Bioressources, Neuralstem, NewLink Genetics, and OHR Pharma
www.prnewswire.com - April 5 at 6:27 AM |
| NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 3 at 5:35 PM |
| NewLink Genetics (NLNK) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 1 at 5:22 PM |
| NewLink Genetics Corp (NLNK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 1 at 1:30 PM |
| Zacks Investment Research Downgrades NewLink Genetics (NLNK) to Hold
www.americanbankingnews.com - April 1 at 12:58 PM |
| $5.78 Million in Sales Expected for NewLink Genetics Corp (NLNK) This Quarter
www.americanbankingnews.com - April 1 at 5:51 AM |
| NewLink Genetics (NLNK) PT Set at $26.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 12:05 PM |
| NewLink Genetics Target of Unusually High Options Trading (NLNK)
www.americanbankingnews.com - March 30 at 7:06 AM |
| -$0.55 EPS Expected for NewLink Genetics Corp (NLNK) This Quarter
www.americanbankingnews.com - March 30 at 3:22 AM |
| Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock March 29, 2018
www.zacks.com - March 29 at 5:30 PM |
| NewLink Genetics (NLNK) Names Chad A. Johnson to Board - StreetInsider.com
www.streetinsider.com - March 23 at 8:19 AM |
| NewLink Genetics Appoints Chad A. Johnson to Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 22 at 8:26 AM |
| NewLink Genetics Appoints Chad A. Johnson to Board of Directors
finance.yahoo.com - March 21 at 5:37 PM |
| NewLink Genetics Announces Presentation of Abstracts at AACR ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:17 AM |
| Factors of Influence in 2018, Key Indicators and Opportunity within NewLink Genetics, Chipmos Technologies, Helen of Troy, InterDigital, Summit Therapeutics, and Kornit Digital — New Research Emphasizes Economic Growth
finance.yahoo.com - March 15 at 8:17 AM |
| NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting
finance.yahoo.com - March 14 at 7:06 PM |
| NewLink Genetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:26 AM |
| Analysts Expect NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - March 12 at 11:06 PM |
| Stock Traders Purchase Large Volume of NewLink Genetics Put Options (NLNK)
www.americanbankingnews.com - March 8 at 8:14 AM |
| NewLink Genetics Corp (NLNK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 7 at 1:51 PM |
| FY2018 Earnings Estimate for NewLink Genetics Corp (NLNK) Issued By Cantor Fitzgerald
www.americanbankingnews.com - March 7 at 11:53 AM |
| NewLink Genetics Corp (NLNK) Expected to Earn Q1 2018 Earnings of ($0.51) Per Share
www.americanbankingnews.com - March 5 at 1:48 AM |
| Hudson Bay Capital Management LP Purchases New Holdings in NewLink Genetics Corp (NLNK)
www.americanbankingnews.com - March 3 at 12:51 PM |
NewLink Genetics (NASDAQ:NLNK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NewLink Genetics (NASDAQ:NLNK) Income Statement, Balance Sheet and Cash Flow Statement
NewLink Genetics (NASDAQ NLNK) Stock Chart for Sunday, April, 22, 2018
Loading chart…
